Scanfil Oyj · OMXHEX:SCANFL

Scanfil Oyj — Scanfil Oyj Ord — Q3 2025 Earnings Presentation

27 slides from Scanfil Oyj's earnings presentation, Oct 24, 2025

  1. Slide 1: Return to Organic Growth

    Return to Organic Growth January-September 2025 24 October 2025 CEO Christophe Sut & CFO Kai Valo

  2. Slide 2: Update on Fire at MB Elettronica Plant in Cortona

    Update on Fire at MB Elettronica Plant in Cortona • Fire started on Friday 17 October, no casualties • Affected one wing and its outgoing goods warehouse • All employees are back to work, and the MB team is ensuring business continuity • Closing of the acquisition is planned to take place in Q4 24-O

  3. Slide 3: Key events in Q3

    Key events in Q3 New sizeable Inauguration of Johor Anna-Maria Acquisition of MB EcoVadis Gold Rating business acquisitions Bahru modernization Tuominen-Reini Elettronica in Italy in August • Stäubli is a global • Modernization of • Mari Tuominen-Reini • Acquisition of MB • Consistent work with indu

  4. Slide 4: Q3 2025 Key Financials

    Q3 2025 Key Financials SCANFIUL

  5. Slide 5: Back to Organic Growth

    Back to Organic Growth • Employee Satisfaction & Motivation +2 points to 72 Q3 2025 • Customer NPS at all time high 54 191.3 M€ / 10.4% • Deals won topped at EUR 72.3 million, highest since Turnover / YoY, % reporting started • Energy & Cleantech returned to growth 7.8% Organic growth, %, YoY • Medt

  6. Slide 6: Turnover and EBITA

    Turnover and EBITA MEUR MEUR 250 20 7.4 7.4 7.4 7.5 7.3 7.3 7.0 6.9 6.9 7.0 15 6.6 200 6.5 6.5 6.3 10 6.0 150 5 5.5 224.6 243.3 212.8 220.8 198.9 195.5 173.3 212.3 192.6 202.2 191.3 15.5 17.9 15.6 13.8 13.1 14.3 12.8 14.7 12.6 14.2 14.1 100 0 5.0 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25

  7. Slide 7: Americas

    Americas 7% 14 12 13 10.5 12.7 10 12 9.3 8.5 11.7 11.8 11 8.1 8 10.8 7.3 7.2 10 6.2 9.7 9.7 6 9 5.4 9.1 5.2 8.8 8.6 8 4 7 2 6 5 0 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Turnover, EUR million Comparable EBITA, % Turnover EBITA Growth initiatives • Positive increased b

  8. Slide 8: APAC

    APAC 28 % 65 12 60 61.1 59.5 10 9.6 55 8.6 53.8 8.4 50 52.2 8 7.9 7.4 7.4 48.4 45 6.9 45.5 6.0 6 42.3 42.7 40 40.1 4.7 35 4 30 2 25 20 0 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Turnover, EUR million Comparable EBITA, % Turnover EBITA Growth initiatives • All customer

  9. Slide 9: Central Europe

    Central Europe 120 10 33 % 100 8.4 8.2 8 97.1 94.8 7.5 7.4 7.5 7.3 7.1 7.1 80 84.6 6.5 76.1 77.2 6 69.5 67.5 60 65.4 63.4 4 40 2 20 0 0 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Turnover, EUR million Comparable EBITA, % Turnover EBITA Growth initiatives • Energy & Clean

  10. Slide 10: Northern Europe

    Northern Europe 33 % 90 10 80 8.6 76.5 8 70 69.1 66.7 67.2 64.7 65.6 60 63.1 6.5 6.5 60.6 6.2 6.1 6.0 56.5 6 50 5.7 5.0 40 4.0 4 30 20 2 10 0 0 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Turnover, EUR million Comparable EBITA, % Turnover EBITA Growth initiatives • High g

  11. Slide 11: Customer Group Development

    Customer Group Development 100% 13% 13% 14% 90% 80% 20 % 43 % 70% 42% 42% 45% 60% 50% 40% 37 % 30% 45% 46% 20% 41% Industrial Energy & Cleantech 10% Medtech & Life Science 0% 2023 2024 Q3 2025 Rest TOP10 (ex. biggest) The biggest customer 24-Oct-25 11

  12. Slide 12: Industrial

    Industrial Turnover Won deals Biggest won deals in Q3 2025 Y/Y: -2.3% 110.0 50 99.9 98.5 27.6 MEUR Logistics 100.0 38.6 94.1 40 90.4 91.1 90.0 31.6 3.0 MEUR Process industry 83.9 30 81.9 24.8 24.8 80.0 2.0 MEUR Entertainment 20 17.5 15.4 70.0 9.3 … … 60.0 10 38.6 MEUR In total 50.0 0 Q1 24 Q2 24 Q3

  13. Slide 13: Energy & Cleantech

    Energy & Cleantech Turnover Won deals Biggest won deals in Q3 2025 Y/Y: 26.1% 80 72.4 30 70.4 67.5 70.1 70 24.8 62.5 64.5 25 22.8 7.0 MEUR General 60 55.6 19.9 20 18.4 3.2 MEUR General 50 16.1 15 40 15 12.1 2.4 MEUR Oil & Gas 30 10 … … 20 5 10 18.4 MEUR In total 0 0 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2

  14. Slide 14: Medtech & Life Science

    Medtech & Life Science Turnover Won deals Biggest won deals in Q3 2025 Y/Y: 16.1% 15.3 15 45.0 40.0 39.3 39.3 4.7 MEUR General Surgery 38.9 37.6 34.4 33.8 10 9.5 3.5 MEUR Ventilation 8.1 8.1 30.0 6.4 3.3 MEUR Ventilation 4.5 4.7 5 … … 15.3 MEUR In total 15.0 0 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3

  15. Slide 15: Financials

    mlarclarersits CFO Kai Valo SCANFIL

  16. Slide 16: Comparable EBITA Waterfall July–September

    Comparable EBITA Waterfall July–September MEUR 10,4% • The turnover in July–September was EUR 12,9% 191.3 million, increase y/y EUR 18.0 million or 10.4%. Negative currency translation difference effect was EUR -4.3 million in Organic turnover, excluding it the turnover increase 7,8% was 12.9%. SRXG

  17. Slide 17: Comparable EBITA Waterfall January–September

    Comparable EBITA Waterfall January–September MEUR 3,2% • The turnover for January–September was EUR 5,1% 586.1 million, increase y/y EUR 18.4 million or 3.2%. Negative currency translation difference effect was EUR -10.7 million in turnover, excluding it the turnover increase was 5.1%. Chg vs LY SRX

  18. Slide 18: Strong Financial Position

    Strong Financial Position EUR 551.3 million • Inventories EUR 167.0 (173.9) million 167.0 • Goodwill EUR 28.1 (7.6) million, increase from Inventories the acquisition of SRXGlobal Pty. Ltd. 297.6 Equity 28.1 Goodwill 17.0 Interest bearing • Cash and cash equivalents totaled EUR 56.0 Other intangible

  19. Slide 19: Strong Cash Generation

    Strong Cash Generation FY 2023: MEUR 68.9 FY 2024: MEUR 92.1 1-9 2025: MEUR 41,4 MEUR • Net cash flow from operating 40 activities in July–September was EUR 7.4 (21.8) million and in January–September EUR 41.4 30 (68.7) million. • Operating cashflow was at a good level. The previous year’s 20 compar

  20. Slide 20: Net Debt Remains at Low Level

    Net Debt Remains at Low Level 120 1.60 • Net debt was EUR 10.4 (11.1) MEUR million 1.40 1.35 • Cash and cash equivalents totaled EUR 56.0 100 (51.8) million 1.15 1.20 • Interest-bearing liabilities were EUR 66.4 (62.9) million 80 1.01 1.00 • Impact of SRX acquisition was neutralized in one year with

  21. Slide 21: Key Figures

    Key Figures • Equity ratio 55.0% (58.2%) Equity Ratio, % ROE, % 59 58.2 16 14.3 • Equity increased by EUR 17.2 million 58 14 12.7 57 12 • Balance sheet was up by EUR 53.1 million 56 55,0 10 55 8 54 53 6 52 4 • Net gearing 3.5% (4.0%) 51 2 50 0 • Net debt was EUR 10.4 million and decreased Q3 2024 Q3

  22. Slide 22: Outlook and focus in 2025

    Outlook and focus in 2025 We expect our turnover to be EUR 780–920 million and comparable EBITA of EUR 55–68 million. Solid operational execution, organic growth and major strategic steps in building company’s future. Focus areas: • Closing of two M&A and financial integration • Keep up the momentum

  23. Slide 23: Q&A

    SCANFIL Q&A

  24. Slide 24: Key takeaways

    Key takeaways • Q3 2025 • Turnover is gaining speed: organic growth was 7.8% and reported 10.4% y/y • EUR/USD effected turnover by EUR -4.3 million and comparable EBITA by EUR -0.3 million • New business pipeline remained strong • Comparable EBITA increased by 10.1% to EUR 14.1. million • Geared for

  25. Slide 25: Contact information and analysts

    Carnegie AB, Stockholm Jakob Söderblom +46 734 178 643 jakob.soderblom@carnegie.se Contact information Inderes Oyj and analysts Antti Viljakainen +358 44 591 2216 antti.viljakainen@inderes.fi Nordea Oyj Pasi Väisänen CHRISTOPHE SUT, CEO +358 9 5300 5192 +358 407 318 411 pasi.vaisanen@nordea.com chri

  26. Slide 26: Disclaimer

    Disclaimer Not to be published or distributed, directly or indirectly, in any country where its distribution or publication is unlawful. Forward looking statements: certain statements in this presentation may constitute "forward-looking" statements which involve known and unknown risks, uncertaintie

  27. Slide 27: Global contract manufacturer and systems supplier

    Global contract manufacturer and systems supplier

Scanfil Oyj Ord — Q3 2025 Earnings Presentation on 6ix